Shares of Hong Kong-listed biotech company Laekna Inc (02105) skyrocketed 43.21% on Wednesday, surging to a 10-month high amid significant investor enthusiasm over the company's announced clinical collaboration with pharmaceutical giant Eli Lilly (LLY).
Under the agreement, Eli Lilly will fund and execute a Phase 1 study of Laekna's experimental obesity treatment LAE102 in the United States. Notably, Laekna retains global rights to the drug, suggesting investors believe this deal could accelerate LAE102's development and approval process while mitigating risk for the smaller biotech firm.
The market's euphoric reaction underscores optimism that the collaboration strengthens the prospects for LAE102's commercial success, given Eli Lilly's extensive resources and expertise. With obesity representing a massive, underserved market, LAE102 is considered a potentially lucrative asset if clinical trials prove the drug's safety and efficacy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。